WASHINGTON, United States (AFP)— A panel of US health experts convened by the Food and Drug Administration are meeting Tuesday to weigh the benefits and risks of using MDMA, commonly known as ecstasy, to treat post-traumatic stress disorder.

PTSD, a debilitating mental health condition that develops after a person experiences or is threatened by traumatic events such as death, combat, or sexual assault, affects an estimated five percent of Americans in any given year.

But pharmaceutical treatment options are so far limited to two antidepressants that require three months of dosing to take effect, and response rates to the medications have been found to be uneven.

California-based Lykos Therapeutics is basing their request for regulatory approval on two clinical studies, each of which enrolled around 100 people, to evaluate MDMA used together with other psychological interventions such as talk therapy, against a placebo with talk therapy.

These two studies, published in the prestigious journal Nature Medicine, indicated MDMA was indeed both safe and highly effective at treating PTSD.

But a briefing document put together by the Food and Drug Administration (FDA) ahead of the meeting suggested its staff were not as convinced.

In particular, they were concerned that although the studies were nominally “double-blinded” — meaning neither those being tested nor their health care workers knew who received the treatment versus the placebo — most people were able to accurately guess what they received.

This “functional unblinding,” they argued, introduces bias and uncertainty into study outcomes.

What’s more, they criticised Lykos for not gathering sufficient side effect data, including whether participants experienced “euphoria” or “elated mood,” which, the FDA argued, “would be informative for an assessment of abuse potential or characterisation of anticipated effects of the drug.”

Reports from recreational use suggest MDMA has harmful impacts on heart and liver health — but the company did not gather enough data in these areas, the FDA said.

Then there are troubling allegations of research impropriety linked to the trials that surfaced in a draft report by the nonprofit Institute for Clinical and Economic Review.

These include claims that the trials “pulled heavily from the existing community of those interested and involved in the use of psychedelics for possible psychological benefits.”

Some patients told the nonprofit they were allegedly prevented from entering the long term-follow up study “and felt this was done to keep these negative outcomes out of the data set.”

“We certainly take those allegations very seriously and are quite concerned by them,” the FDA’s Tiffany Farchione said during the meeting, adding a probe was ongoing.

MDMA — methylenedioxymethamphetamine — is a Schedule 1 drug under the Controlled Substances Act, and approving it for medical use would represent a major shift.

But even if the FDA advisers endorse MDMA, their vote is non-binding and the final decision on whether to approve the treatment rests with the agency.

And final authorisation may come with certain strict stipulations attached, for example that the drug only be dispensed in health care settings, with subjects carefully monitored and enrolled in a registry to document side effects.